Medical Affairs Reputations: Chronic Lymphocytic Leukaemia (EU5) 2018

Maximum Purchase:
1 unit
Publication Date:
September 2018
Adding to cart… The item has been added

Close rivalries among European CLL medical affairs teams. Will your team come out on top?

In Europe, two CLL medical affairs teams are duking it out for top spot, with only 0.1 of a point separating them. Not only that, third place is nearly six points adrift. What are the leading teams doing so well? Can other teams close the gap? And how are biosimilars faring? 150 medical oncologists and haematologists from the EU5 markets (France, Germany, Italy, Spain and the UK) provide insights on several medical affairs teams, and opinions are mixed. Will targeting improvements in certain areas be enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: CLL (EU5) [2018]. This report, which compares the current activities of medical affairs teams for the 8 leading treatments for CLL from Novartis, Roche, Sandoz, AbbVie, Janssen and Napp, reveals:

  • How medical oncologists and haematologists rate your team overall, and on 12 key medical affairs services
  • Which medical affairs services are most important.
  • How, and how often medical oncologists and haematologists want to meet with your team.
  • What you can do to improve your medical affairs services.

That’s actionable information you can use to turn your team into one that doctors rely on.

Interested in the US market? Click here to see the US Edition.

Request sample pages

Top Takeaways

  • Which brands are tussling at the top? Only 0.1 points separate the top two brands from each other. And their lead is significant. What ‘sweetspot’ have these teams hit on? And can they be chased down?
  • Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions, with nearly all teams tasked with improving in this area.
  • High levels of physician interaction. In the past six months, all six medical affairs teams have interacted with 65 percent or more of the doctors surveyed, with the most active seeing over 90 percent of them.
  • How often should medical affairs teams visit? Given a choice of interaction frequency, medical oncologists and haematologists were split in their preference? Learn more about this in the report.

Insight into Medical Affairs Teams for 8 CLL Treatments

  • Arzerra (ofatumumab; Novartis)
  • Gazyvaro (obinutuzumab; Roche)
  • Imbruvica (ibrutinib; AbbVie/Janssen Cilag)
  • MabThera (rituximab, Roche)
  • Venclyxto (venetoclax; AbbVie/Roche)
  • Zydelig (idelalisib; Gilead)
  • Rixathon (rituximab; Sandoz)
  • Truxima (rituximab; Celltrion/Napp/Mundipharma)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important questions like:

What do doctors need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team’s interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition—in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 medical oncologists and haematologists from the EU5 (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with CLL in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product’s medical affairs team in the past 6 months

We conducted the survey between September 5-13, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at